Aerovate Therapeutics, Inc. (AVTE)

Aerovate Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-84.61	-75.52	-51.51	-22.96	-9.61	-3.33
Depreciation & Amortization	0.3	0.1	0.07	0.02	0	-
Loss (Gain) From Sale of Investments	-2.85	-3.06	-0.91	0.02	-	-
Stock-Based Compensation	13.32	11.91	5.48	2.04	0.06	-
Other Operating Activities	-	-	-	-	0.72	-
Change in Accounts Payable	-2.53	-0.16	1.37	0.61	0.04	0.44
Change in Other Net Operating Assets	1.42	9.96	6.39	-7.12	0.94	0.11
Operating Cash Flow	-74.95	-56.78	-39.12	-27.4	-7.86	-2.78
Capital Expenditures	-0.06	-0.14	-0.2	-0.18	-	-
Investment in Securities	48.61	12.02	7.12	-113.25	-	-
Investing Cash Flow	48.55	11.88	6.93	-113.43	-	-
Short-Term Debt Issued	-	-	-	-	2.5	2.5
Total Debt Issued	-	-	-	-	2.5	2.5
Net Debt Issued (Repaid)	-	-	-	-	2.5	2.5
Issuance of Common Stock	25.64	46.23	0.77	126.95	0.01	-
Other Financing Activities	-0.31	-0.23	-0.37	-	-	-
Financing Cash Flow	25.34	46	0.4	190.46	8.92	2.5
Net Cash Flow	-1.07	1.09	-31.8	49.62	1.06	-0.28
Free Cash Flow	-75.01	-56.92	-39.32	-27.58	-7.86	-2.78
Free Cash Flow Per Share	-2.65	-2.16	-1.61	-2.24	-32.44	-11.52
Levered Free Cash Flow	-46.74	-28.72	-18.2	-18.78	-4.53	-
Unlevered Free Cash Flow	-46.74	-28.72	-18.2	-18.78	-4.48	-
Change in Net Working Capital	3.89	-10.3	-9.72	6.27	-1.01	-

Source: S&P Capital IQ. Standard template. Financial Sources.